A share price of Edwards Lifesciences Corp [EW] is currently trading at $90.05, up 0.95%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EW shares have lost -3.22% over the last week, with a monthly amount drifted -2.45%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Edwards Lifesciences Corp [NYSE: EW] stock has seen the most recent analyst activity on March 07, 2024, when BofA Securities upgraded its rating to a Buy. Previously, Wells Fargo upgraded its rating to Overweight on February 02, 2024, and kept the price target unchanged to $94. On January 04, 2024, downgrade downgraded it’s rating to In-line and revised its price target to $77 on the stock. Citigroup downgraded its rating to a Neutral. Wolfe Research downgraded its rating to a Underperform but $57 remained the price target by the analyst firm on November 28, 2023. Oppenheimer upgraded its rating to Outperform for this stock on September 26, 2023, but kept the price target unchanged to $90. In a note dated July 19, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $107 on this stock.
Edwards Lifesciences Corp experienced fluctuations in its stock price throughout the past year between $60.57 and $96.12. Currently, Wall Street analysts expect the stock to reach $111.56 within the next 12 months. Edwards Lifesciences Corp [NYSE: EW] shares were valued at $90.05 at the most recent close of the market. An investor can expect a potential return of 23.89% based on the average EW price forecast.
Analyzing the EW fundamentals
Trailing Twelve Months sales for Edwards Lifesciences Corp [NYSE:EW] were 6.00B which represents 13.78% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.22 and Total Capital is 0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.48 points at the first support level, and at 86.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.01, and for the 2nd resistance point, it is at 91.97.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Edwards Lifesciences Corp [NYSE:EW] is 3.38. As well, the Quick Ratio is 2.40, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 9.02, the price to book ratio is 8.14 and price to earnings (TTM) ratio is 39.12.
Transactions by insiders
Recent insider trading involved Lippis Daniel J., CVP, JAPAC, that happened on Apr 09 ’24 when 857.0 shares were sold. CVP, EMEACLA, Lemercier Jean-Luc M completed a deal on Apr 08 ’24 to sell 14400.0 shares. Meanwhile, CVP,Strategy/Corp Development BOBO DONALD E JR sold 12500.0 shares on Apr 08 ’24.
